Find Clinical Trials

Inclusion Criteria: * 1\. Patients above 40 years old. 2\. POAG who underwent previous uncomplicated cataract surgery with intraocular lens implantation. 3\. Pseudophakic patients with medically uncontrolled glaucoma in spite of the use of two anti-glaucoma medications or intolerance to medical therapy. 4\. Visual field defects in both the superior and inferior hemi-fields outside the central 5 degrees of fixation. 5\. Mean deviation on perimetry ranges between -6 dB and -12 dB Exclusion Criteria: * 1\. Patients with history of previous glaucoma surgery. 2. Patients who have used topical steroids within the last three months. 3. Patients with significant media opacity, such as corneal opacity, that obstructs fundoscopic examination. 4\. Patients with ocular diseases as uveitis. 5. Patients with severe ocular surface disorders as ocular cicatricial pemphigoid. 6\. Aphakic patients. 7. Ocular interventions apart from YAG posterior capsulotomy.

Inclusion Criteria: * Adults aged 18 years or older * Pulmonary artery systolic pressure (PASP) ≥35 mmHg as estimated by echocardiography * Provided written informed consent Exclusion Criteria: * Severe hepatic or renal insufficiency * Malignancy under active treatment * Severe infection * Active autoimmune disease * Major surgery within the past 3 months * Pregnant or breastfeeding women * Severe psychiatric disorder impairing ability to comply with the study protocol

Inclusion Criteria: * Between the ages of 19 and 40 years * Verbally fluent in English (i.e., must be able to speak or understand English) * No uncorrected visual or hearing impairment * Moderate depressive symptoms or greater of at least 10 or higher on the Patient Health Questionnaire-8 screening instrument * Eligible to participate in physical activity * Physically inactive (i.e., engaging in less than 150 min of weekly moderate-to-vigorous physical activity) * Owns an Apple or Android mobile device, willing to download the Pathverse app , and willing to keep the device on during the study period * Not currently pregnant Exclusion Criteria: \- Participants will not qualify for the current study if they do not meet the above inclusion criteria.

Inclusion Criteria: 1. Male or female 2. 15 years and older 3. Able to provide informed consent or/and assent 4. Diagnosed with major depressive disorder (MDD) and currently experiencing a major depressive episode (MDE) 5. Adult participants failed to respond to at least one prior anti-depressant medication; for adolescent participants, TMS therapy is used as an adjunct treatment as stated in the FDA cleared indications, but failure to respond adequately to prior anti-depressant medication is not required 6. Participant prescribed TMS Therapy to treat MDD by his or her physician independent of potential participation in this clinical study 7. On a stable antidepressant treatment regimen (whether medication, therapy, other methods or no treatment at all) for at least the past 4 weeks and agrees to remain on the same treatment regimen throughout study enrollment 8. Willing to comply with all the study procedures, complete required assessments and visits, and be available for the duration of the study Exclusion Criteria: 1. Participants satisfy any one or more of the contraindications for TMS per current treatment guidelines as determined by the PI 2. Total MADRS score of \< 20 or PHQ-score \<10 at the screen or baseline visits 3. Current diagnosis of substance use disorder (Abuse or Dependence, as defined by DSM-V-TR), with the exception of nicotine dependence 4. Displaying symptoms of substance withdrawal 5. History of schizophrenia or schizoaffective disorders, or any history of psychotic symptoms in the current or previous depressive episodes 6. Any disorder which at screening is clinically predominant to their MDD or has been predominant to their MDD at any time within six months prior to screening 7. Has a clinically significant abnormality on the screening examination that might affect safety, study participation, or confound interpretation of study results 8. Participation in any clinical trial with an investigational drug or device within the past month or concurrent to study participation 9. History of non-response to TMS or ECT 10. History of any implanted device or psychosurgery for depression 11. PI opinion: Considered at significant risk for suicide during the course of the study 12. Have any medical or psychological condition, that in the opinion of the referring psychiatrist or investigator, would prevent the participant from completing the study, put the participant at unacceptable risk or could interfere with study assessments or integrity of the data

Inclusion Criteria: * Pathologically confirmed HER-2 positive breast cancer (immunohistochemistry 3+ or 2+ with FISH positivity).Diagnosis of advanced breast cancer in accordance with AJCC staging criteria. * Achieved complete response (CR) as evaluated by PET-CT or contrast-enhanced CT after receiving salvage therapy (within second-line) and maintained for 3 months. * Negative ctDNA-MRD (circulating tumor DNA - minimal residual disease) detection. * Negative CA153 detection. * ECOG performance status score of 0-2. * Expected survival ≥ 6 months. * The patient has signed an informed consent form, willing to cooperate with the study and accept regular follow-up. Exclusion Criteria: * Concomitant other malignant tumors (excluding breast cancer). * History of mental disorders or cognitive dysfunction, unable to cooperate with the study. * Pregnant or lactating women. * Severe cardiac, hepatic, or renal insufficiency. * Currently participating in other clinical trials that may affect the evaluation of this study's results.

Inclusion Criteria: * Female * Aged \> 18 * Undergoing immediate breast reconstruction (autologous or implant based) follow mastectomy for breast cancer or as a risk-reducing strategy * Available to attend 3D-SI appointments at specified intervals Exclusion Criteria: * Lack of capacity * Language barrier that prevents patients from understanding the English questionnaires * Visual impairment * Unable to answer study questionnaires * Disability that may prevent appropriate positioning during the imaging process * Unable to attend for photography * Requiring delayed reconstruction or no longer considering a reconstruction

Inclusion Criteria: * Patients with a definite diagnosis of malignancy by histopathology and/or cytology; * Age ≥18 years; * There is no gender limit * Plan to receive antineoplastic therapy within 2 weeks or are receiving standard antineoplastic care (surgery, radiation, chemotherapy, or targeted therapy) ; * Conscious and able to answer questions and use electronic devices autonomously; * Patients were able to understand the study and voluntarily sign an informed consent form; Exclusion Criteria: * Having severe mental or cognitive impairments that prevent them from understanding the content of the study or implementing the programme; * With severe heart disease, acute respiratory failure, liver kidney failure and other critical illness; * Women during pregnancy or lactation； * Have participated in other interventional studies in the past 1 month or are currently participating; * Patients with ECOG ≥ 3 that do not respond to treatment; * Patients with an expected survival of \< 3 months that do not respond to treatment; * Cases deemed unsuitable for enrollment by the investigator.

Inclusion Criteria: * Successfully enrolled and ready to begin the VDOP program not on insulin therapy * Type 2 diabetes by clinical history * HbA1C between 8.0-12.0% inclusive within 3 months of enrollment * Assessment by clinician that patient is willing to and able to wear a CGM device * Stable diabetes medication regimen during the 3 months prior to entry Exclusion Criteria: * Patients already or planned on starting insulin therapy, already on CGM, or those who qualify for CGM under VA policy * Patients with gestational diabetes or pregnant at time of screening or are planning to become pregnant during the study * Patients with end stage renal disease (ESRD) on dialysis * Anticipated acute uses of glucocorticoids (oral, injectable, or IV) * Acute conditions that impact the HbA1c measurement stability such as GI blood loss, recent (within 3 months of study entry), anticipated red blood cell transfusion or erythropoietin administration * Known or suspected significant allergy to use the Dexcom sensors * Planning or currently enrolled on different weight program different from MOVE! * Participating other clinical trials

Inclusion Criteria: * PHQ or GAD cutoff 5 or above * Residing in Norway and have a Norwegian national identity number * 16 years or above Exclusion Criteria: * Reporting 2 or higher on PHQ item 9 (suicidality concerns) * Do not comprehend Norwegian or English

Inclusion Criteria: 1. Age 18 years and older 2. Patients selected for PreserFlo microshunt surgery and XEN stent alone or in combination with cataract surgery. 3. Ability to comprehend the study procedures Exclusion Criteria: 1. Unwilling or unable to give consent 2. Unable to come for scheduled post-operative visits 3. Pregnant or nursing women 4. Previous cyclodestructive procedures, scleral buckling procedures, or presence of silicone oil 5. Conjunctival scarring precluding a glaucoma surgery superiorly 6. Active iris neovascularization or active proliferative retinopathy 7. Vitreous in the anterior chamber for which a vitrectomy is anticipated. 8. Previous trabeculectomy, tube-shunt implantation, or surgeries that shunt aqueous outflow into the subconjunctival space

Inclusion Criteria: * Prolific users ages 18-25 * Must reside in the U.S. * Must have access to a smart device, and are willing to download an external app (screened by Prolific Academic) * Must complete screening form which consists of the Patient Health Questionnaire (PHQ-2) and the Generalized Anxiety Disorder (GAD-7) Scale. * Must have mild to moderate depressive or anxiety symptoms, as measured by the screening form Exclusion Criteria: \- None

Inclusion Criteria for breast cancer survivors: * Being a woman * Being between the ages of 25 and 75 * Having been diagnosed with Stage 0-III breast cancer * Having completed primary treatments (surgery, chemotherapy, and/or radiation therapy) no more than 6 months prior to the assessment date * Having received medical clearance from a physician * Having undergone either breast-conserving surgery or mastectomy due to breast cancer * Willingness to participate in the study voluntarily Exclusion Criteria for breast cancer survivors: * Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within 6 months prior to the breast cancer diagnosis * Having a history of neuromuscular dysfunction * Using medications that may affect neuromuscular performance Inclusion criteria for the control group: * Being a woman * Having a body mass index (BMI) within ±3 kg/m² of the breast cancer survivor group * Being within ±5 years of age compared to the breast cancer survivor group * Matching hand dominance with the breast cancer survivor group Exclusion criteria for the control group: * Having a history of neuromuscular dysfunction * Using medications that may affect neuromuscular performance * Having a history of rehabilitation due to upper extremity, thoracic, or cervical musculoskeletal disorders within the last 6 months

Inclusion Criteria: * Patients of both sexes; * Individuals with venous ulcers in the lower limbs for at least three weeks that have not healed; * Age between 18 and 85 years; * Residents of Lençóis Paulista or nearby regions. Exclusion Criteria: * Patients with ulcers of non-venous etiology; * Pregnant women; * Presence of severe arterial disease in the lower limbs.

Inclusion Criteria: * Pregnant women who lived in Jimma City for at least six months * Women with a gestational age between 12 and 28 weeks, * Women who scored EPDS ≥ 13, * Willing to participate for eight consecutive weeks, * Able to attend the health center three times per week and gave consent to be followed up by study supervisors and data collectors Exclusion Criteria: * Having been diagnosed with mental health disorders or eating disorders, * Active substance use, * EPDS item 10 score ≥1 or total EPDS score \>19, * Currently receiving pharmacological or psychotherapeutic treatment, * Regularly practice meditation, * Severely ill, * Has active pregnancy-related complications that could interfere with attending the mindfulness exercise, or neurological conditions such as epilepsy or seizures

Inclusion Criteria Adults aged 18 to 70 years. Confirmed diagnosis of Type 2 diabetes mellitus. Inadequate glycaemic control while receiving a stable dose of metformin. Inclusion Criteria: * Adults aged 18 to 70 years. * Confirmed diagnosis of Type 2 diabetes mellitus. * Inadequate glycaemic control while receiving a stable dose of metformin. * HbA1c within the protocol-defined screening range. * Body mass index (BMI) 25 to 40 kg/m². * Adequate renal function. * Able and willing to provide written informed consent and comply with study procedures. Exclusion Criteria: * Type 1 diabetes mellitus or history of diabetic ketoacidosis. * Use of prohibited glucose-lowering medications before screening. * Clinically significant renal, hepatic, gastrointestinal, cardiovascular, or other medical conditions that could interfere with study participation or safety. * Recent major cardiovascular event or unstable cardiovascular disease. * Previous bariatric surgery or recent treatment with anti-obesity medication. * Active infection or other uncontrolled medical condition. * Pregnant or breastfeeding, or unwilling to comply with protocol-required contraception. * Any condition that, in the investigator's opinion, would make participation unsuitable or compromise the study.

Participants will be enrolled into the RCT only if they meet all the inclusion criteria and none of the exclusion criteria. Inclusion Criteria: * Identifies as trans, non-binary, or gender diverse * Is between the ages of 12 and 17 years inclusive * Has completed primary school at the time of enrolment into the study * Has current psychological stress symptomology as determined by a score of moderate or above on the DASS-Y * Provide informed consent: All participants and parent/legal guardians must be willing to give informed consent Exclusion Criteria: * Has current acute suicidal symptomology as determined by a combination of clinical judgement and the results of the Ask Suicide-Screening Questions (ASQ) suicide screening tool (e.g., answer yes to question 5) to determine the risk of suicide (has an active plan and/or intent to suicide) at time of screening interview * Is actively having treatment with any other group psychological intervention at the time of enrolment into the study * Is not proficient in English (as the group Cognitive behaviour therapy (CBT) program will be delivered in English and funds aren't available for interpreters) * Previous participation in the feasibility trial * Is currently enrolled in tertiary study (e.g., undergraduate university)

Inclusion Criteria: * Adult patients of Black African descent scheduled to undergo DSLT treatment in one or both eyes. * Diagnosis of mild to moderate primary open angle glaucoma (POAG). * Mild to moderate POAG will be defined as Stage 2 or better of the Hodapp-Anderson-Parrish glaucoma staging system. * Treatment naive or washed out IOP at time 0 ranging from ≥ 21 through 32 mm Hg. Exclusion Criteria: * Screened patients who were on IOP-lowering medications who did not successfully complete medication washout at the time of the procedure (time 0). * Previous glaucoma surgeries/interventions: * Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt). * Secondary glaucoma: * Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases. * Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator. * Subjects who are pregnant, breast-feeding, or intend to become pregnant during the study period as determined by verbal inquiry.

Inclusion Criteria: 1. Aged between 18 and 80 years. 2. Meets the definition of difficult to control type 2 diabetes: HbA1c level between 7.5% and 11.5%, AND Taking 3 or more anti-hyperglycemic drugs. OR Taking insulin and other anti-hyperglycemic drugs. OR Taking 2 or more anti-hyperglycemic drugs AND a.) the presence of 1 or more micro-vascular or macro-vascular complication (retinopathy, diabetic nephropathy and chronic kidney disease, diabetic neuropathy, atherosclerotic heart disease with diabetes); AND/OR b.) concomitant hypertension requiring 2 or more anti-hypertension medications. Exclusion Criteria: 1. Patients with Type 1 diabetes, new-onset diabetes (\<1 year duration), or other specific types of diabetes. 2. History of systemic glucocorticoid use within the last 3 months (inhaled or topical agents are not exclusionary). 3. Pregnant or lactating. 4. Presence of severe cardiac, hepatic, renal, or other major organ dysfunction. 5. History of acute diabetic complications, such as diabetic ketoacidosis or hyperosmolar hyperglycemic state, within the last 3 months. 6. Presence of diseases that significantly affect metabolism, such as malignancy or autoimmune disorders. 7. Inability to tolerate adhesive tape, severe skin conditions at the sensor placement site, or presence of a psychiatric illness or cognitive impairment that would interfere with study compliance. 8. A known diagnosis of Cushing's syndrome, or currently receiving treatment with any of the following: mifepristone, metyrapone, osilodrostat, ketoconazole, fluconazole, aminoglutethimide, etomidate, octreotide, larazotide, long-acting octreotide, or pasireotide. 9. Excessive alcohol consumption (defined as \>14 units per week for males or \>7 units per week for females). 10. Severe, untreated sleep apnea. 11. Night shift workers (defined as being awake between 11:00 PM and 7:00 AM). 12. Known allergy or severe reaction to dexamethasone.

Inclusion Criteria: 1. Adults aged between 18 and 65 years (to avoid the risk of cataract associated with light therapy) with a diagnosis of a major depressive episode (MDE) in the context of unipolar depression (according to DSM-5 criteria). 2. Diagnosis of comorbid insomnia with the MDE, defined by difficulty initiating sleep, and/or maintaining sleep, and/or early morning awakenings with daytime consequences, occurring at least three times per week (according to DSM-5 and ICSD-3, in line with European guideline recommendations). 3. Outpatients or inpatients treated for MDE in one of the psychiatric departments of the study centers, or in the sleep medicine department, for a minimum treatment duration of 8 weeks. 4. Patients not currently receiving antidepressant treatment for the current MDE (previous use of antidepressants is allowed, provided treatment was stopped at least one month prior to study participation). 5. A MADRS score ≥ 20 (clinician-rated), indicating at least a moderate-intensity depressive episode. 6. An ISI score ≥ 8 (clinician-rated), indicating at least mild and clinically significant insomnia. 7. No exposure to light therapy in the month prior to inclusion. 8. Ability to understand and sign the informed consent form. 9. Use of highly effective contraception for women of childbearing potential. Exclusion Criteria: 1. Individuals under legal guardianship or deprived of liberty 2. Ophthalmologic conditions (e.g., cataract, glaucoma, age-related macular degeneration) or diseases affecting the retina (e.g., retinitis pigmentosa, diabetes, herpes, etc.) 3. The following disorders (according to DSM-5): schizophrenia and other psychotic disorders; bipolar disorder, particularly (hypo)manic episodes (YMRS score ≥ 12); other unstable mental disorders 4. Other unstable general medical conditions 5. Pregnant or breastfeeding women 6. Hypersomnia with prolonged total sleep time secondary to the depressive episode, according to ICSD-3 criteria 7. Current depressive episode already being treated with an antidepressant 8. Presence of a high suicidal risk, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS, score ≥ 4) 9. Ongoing melatonin treatment at the time of inclusion

Inclusion Criteria: * Patients ≥ 18 years old. * DCIS or invasive breast cancer, confirmed by biopsy * Clinically node-negative, confirmed by preoperative axillary ultrasound * Indication for breast cancer surgery with SLN procedure via axillar incision Exclusion Criteria: * Combined MARI procedure * Known allergy for Indocyanine Green (ICG), intravenous contrast or iodine * History of axillary lymph node dissection * Hyperthyroidism or thyroid cancer * Pregnancy or breast-feeding * No written informed consent according to ICH/GCP and national regulations.